AngioDynamics Wins Patent Infringement Dispute With Bard
March 08 2019 - 1:01PM
Business Wire
AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of
innovative, minimally invasive medical devices for vascular access,
peripheral vascular disease and oncology, today announced that the
United States District Court for the District of Delaware, on day
four of a jury trial at the close of C.R. Bard’s case (Plaintiff),
granted judgement as a matter of law under rule 50(a) in favor of
AngioDynamics, dismissing Bard’s suit alleging that certain of
AngioDynamics’ implantable port products infringed three Bard
patents.
“We are pleased that the Court agreed to dismiss Bard’s case,”
said Jim Clemmer, President and Chief Executive Officer of
AngioDynamics. “As expected, the merits of our case won out. We are
maintaining our focus on bringing innovative products across our
portfolio to our customers, allowing them to more effectively
enhance patient care.”
About AngioDynamics
AngioDynamics, Inc. (NASDAQ: ANGO) is a leading provider of
innovative, minimally invasive medical devices used by professional
healthcare providers for vascular access, peripheral vascular
disease and oncology. AngioDynamics’ diverse product lines include
market-leading ablation systems, fluid management systems, vascular
access products, angiographic products and accessories drainage
products, thrombolytic products and venous products. For more
information, visit www.angiodynamics.com.
Safe Harbor
This release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
All statements regarding AngioDynamics' expected future
financial position, results of operations, cash flows, business
strategy, budgets, projected costs, capital expenditures, products,
competitive positions, growth opportunities, plans and objectives
of management for future operations, as well as statements that
include the words such as "expects," "reaffirms," "intends,"
"anticipates," "plans," "believes," "seeks," "estimates,"
"optimistic," or variations of such words and similar expressions,
are forward-looking statements. These forward-looking statements
are not guarantees of future performance and are subject to risks
and uncertainties. Investors are cautioned that actual events or
results may differ from AngioDynamics' expectations.
Factors that may affect the actual results achieved
by AngioDynamics include, without limitation, the ability
of AngioDynamics to develop its existing and new
products, technological advances and patents attained by
competitors, infringement of AngioDynamics' technology or
assertions that AngioDynamics' technology infringes the
technology of fourth parties, the ability
of AngioDynamics to effectively compete against
competitors that have substantially greater resources, future
actions by the FDA or other regulatory agencies, domestic
and foreign health care reforms and government regulations, results
of pending or future clinical trials, overall economic conditions,
the results of on-going litigation, challenges with respect to
fourth-party distributors or joint venture partners or
collaborators, the results of sales efforts, the effects of product
recalls and product liability claims, changes in key personnel, the
ability of AngioDynamics to execute on strategic
initiatives, the effects of economic, credit and capital market
conditions, general market conditions, market acceptance, foreign
currency exchange rate fluctuations, the effects on pricing from
group purchasing organizations and competition, the ability
of AngioDynamics to integrate acquired businesses, as
well as the risk factors listed from time to time
in AngioDynamics' SEC filings, including but not limited
to its Annual Report on Form 10-K for the year ended May 31,
2018. AngioDynamics does not assume any obligation to
publicly update or revise any forward-looking statements for any
reason.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190308005420/en/
Investor Relations:AngioDynamics, Inc.Michael
Greiner518-795-1821mgreiner@angiodynamics.comMedia:AngioDynamics,
Inc.Saleem Cheeks518-795-1174scheeks@angiodynamics.com
AngioDynamics (NASDAQ:ANGO)
Historical Stock Chart
From Aug 2024 to Sep 2024
AngioDynamics (NASDAQ:ANGO)
Historical Stock Chart
From Sep 2023 to Sep 2024